---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-056783"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:53:22.778643+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edgewise Q1 net loss $49M, cash $499.6M; sevasemten Becker data up to 3.5 years

## Summary
- Net loss $49.0M ($0.46/share) in Q1 2026 vs $40.8M ($0.43/share) in Q1 2025; cash and equivalents $499.6M.
- R&D expense $42.7M (up 16% YoY) driven by EDG-7500 and EDG-15400 clinical activity, partly offset by lower sevasemten costs.
- Long-term MESA OLE data shows sevasemten stabilizes function in Becker up to 3.5 years; 99% enrollment from prior trials.
- Pivotal GRAND CANYON sevasemten top-line results expected Q4 2026; marketing application planned H1 2027.
- CIRRUS-HCM Part D (EDG-7500) 12-week data in HCM expected Q2 2026; Phase 3 initiation H2 2026.

## SEC filing metadata
- accession: 0001104659-26-056783
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465926056783/0001104659-26-056783-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465926056783/tm2613489d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-056783
- JSON: https://secwatch.observer/filing/0001104659-26-056783.json
- Plain text: https://secwatch.observer/filing/0001104659-26-056783.txt

## Source-grounded claims
- claim_id: d33539546409cb4bd271047977e3ed399509318b
  claim: Edgewise Therapeutics, Inc. reported financial results for first quarter of 2026.
  evidence_excerpt: Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000110465926056783/0001104659-26-056783-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.